Akebia Therapeutics (AKBA) Reports Q4 results

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 Revenue for the quarter at $56.2 million versus the consensus estimate of $55.89 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Dare Bioscience (DARE) Tops Q2 EPS by 11c
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c